FATE (Fate Therapeutics) Current Accrued Expense: $14.90 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FATE Fate Therapeutics Inc FATE
33 GF Score
Price $2.57
GF Value $0.79
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Fate Therapeutics Current Accrued Expense?

Fate Therapeutics FATE +1.98% 33 Current Accrued Expense is $14.90 Mil as of Jun. 2026. GuruFocus rates FATE with a GF Score™ of 33/100 and a GF Value™ of $0.79 (Significantly Overvalued). The stock has 7 warning signs investors should review.

Fate Therapeutics's Current Accrued Expense for the quarter that ended in Jun. 2026 was $14.90 Mil.

Fate Therapeutics's quarterly Current Accrued Expense declined from Dec. 2025 ($20.02 Mil) to Mar. 2026 ($13.64 Mil) but then increased from Mar. 2026 ($13.64 Mil) to Jun. 2026 ($14.90 Mil).

Fate Therapeutics's annual Current Accrued Expense declined from Dec. 2023 ($27.51 Mil) to Dec. 2024 ($21.35 Mil) and declined from Dec. 2024 ($21.35 Mil) to Dec. 2025 ($20.02 Mil).

Fate Therapeutics Current Accrued Expense Related Terms

Fate Therapeutics Current Accrued Expense Historical Data

* Premium members only.

The historical data trend for Fate Therapeutics's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Fate Therapeutics Current Accrued Expense Chart

Fate Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Current Accrued Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 42.41 53.93 27.51 21.35 20.02

Fate Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Current Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 18.18 17.57 20.02 13.64 14.90
FATE
33GF Score
Fate Therapeutics Inc FATE
Current Accrued Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Fate Therapeutics Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

What does a Current Accrued Expense of $14.90 Mil mean?
Fate Therapeutics (FATE) has a Current Accrued Expense of $14.90 Mil as of Jun. 2026. Current Accrued Expense records the total amount of accrued expenses. View historical data on Fate Therapeutics and its competitors.
Is Fate Therapeutics' Current Accrued Expense too high?
Fate Therapeutics' current Current Accrued Expense is $14.90 Mil. Overall, Fate Therapeutics has a GF Score™ of 33/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Fate Therapeutics' Current Accrued Expense compare to IMRX and NWBO?
Fate Therapeutics' Current Accrued Expense of $14.90 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Accrued Expense for a Biotechnology company?
A good Current Accrued Expense depends on the Biotechnology industry context. However, Current Accrued Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Accrued Expense mean?
A high Current Accrued Expense can signal that a stock is expensive relative to its fundamentals. Current Accrued Expense records the total amount of accrued expenses. View historical data on Fate Therapeutics and its competitors. Fate Therapeutics's current Current Accrued Expense is $14.90 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fate Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Fate Therapeutics (FATE) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.79, compared to a current price of $2.57 — trading 224.7% above its estimated fair value. The current Current Accrued Expense is $14.90 Mil. Fate Therapeutics' overall GF Score™ is 33/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Accrued Expense calculated?
Current Accrued Expense is calculated from a company's financial statements. For Fate Therapeutics (FATE), the current Current Accrued Expense is $14.90 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Fate Therapeutics (FATE) Overvalued in 2026?

Based on GuruFocus' analysis, Fate Therapeutics stock appears to be overvalued. The current stock price of $2.57 is trading 224.7% above its estimated GF Value™ of $0.79. GuruFocus considers Fate Therapeutics to be Significantly Overvalued.

Key valuation signals for FATE:

  • Current Accrued Expense: $14.90 Mil
  • GF Value™: $0.79 vs. price of $2.57 (224.7% above fair value)
  • GF Score™: 33/100 with 7 warning signs

No single metric tells the full story. See the FATE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Fate Therapeutics Business Description

Other Exchanges F6T:Germany
Address 12278 Scripps Summit Drive, San Diego, CA, USA, 92131
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. The company is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.
33GF Score

Get the complete analysis for FATE

Current Accrued Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.57
Price
$0.79
GF Value